Oncology Data Advisor - Data Hub: Genitourinary Cancers

Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles, MD, MBBS, MRCP

In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.

Exploring the TALAPRO-2 Study of Talazoparib and Enzalutamide in Prostate Cancer: Stephen Freedland, MD, and Neeraj Agarwal, MD

In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, speaks with Dr. Neeraj Agarwal, Director of the Genitourinary (GU) Medical Oncology Group at Huntsman Cancer I...

Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD

The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCRPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology ...

Great American Smokeout: The Link Between Smoking and Prostate Cancer With Stephen Freedland, MD

In honor of the Great American Smokeout, Oncology Data Advisor sat down with Stephen Freedland, MD, the Director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Medical Center, to discuss the impact that smoking has on p...

Exploring the TALAPRO-2 Study of Talazoparib and Enzalutamide in Prostate Cancer: Stephen Freedland, MD, and Neeraj Agarwal, MD

Oncology Data Advisor® · TALAPRO-2 (Talazoparib + Enzalutamide) in Prostate Cancer: Stephen Freedland and Neeraj Agarwal In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-...

Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD

Oncology Data Advisor® · Enzalutamide Approved for Nonmetastatic CSPC With Biochemical Recurrence: Stephen Freedland, MD The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prost...

Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD

Oncology Data Advisor® · Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approv...

Enzalutamide Approved for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence

The FDA has approved enzalutamide (Xtandi®, Astellas Pharma US, Inc.) for nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). Why it matters: "Within 10 years fol...

Niraparib and Abiraterone Acetate Plus Prednisone Approved for BRCA-Mutated Metastatic CRPC

The FDA has approved the fixed dose combination of niraparib and abiraterone acetate (Akeega™, Janssen Biotech), plus prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cance...

Trifluridine and Tipiracil Plus Bevacizumab Approved for Previously Treated Metastatic Colorectal Cancer

The FDA has approved trifluridine and tipiracil (Lonsurf®, Taiho Oncology, Inc.) in combination with bevacizumab (Avastin®, Genentech, Inc.) for treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated wit...